Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma08/03/2024
FDA and EMA Accept Vorasidenib Regulatory Submissions for Marketing Approval of Vorasidenib for the Treatment of IDH-mutant Diffuse Glioma 20/02/2024
